Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:DRNA NASDAQ:MORF NASDAQ:NGM NASDAQ:RVNC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$108.98-1.6%$106.51$72.21▼$139.13$5.37B0.46668,655 shs978,142 shsDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AMORFMorphic$56.99$56.76$19.34▼$57.00$2.85B1.491.27 million shs400 shsNGMNGM Biopharmaceuticals$1.54$1.55$0.60▼$4.69$128.53M1.271.47 million shsN/ARVNCRevance Therapeutics$3.65$3.65$2.76▼$6.65$381.02M0.93.70 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics0.00%+3.44%+2.57%+11.14%+32.10%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MORFMorphic0.00%0.00%0.00%0.00%+2.24%NGMNGM Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%+25.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXSMAxsome Therapeutics4.7671 of 5 stars4.51.00.04.52.74.20.6DRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMORFMorphic0.9963 of 5 stars1.00.00.04.80.03.30.0NGMNGM Biopharmaceuticals1.5917 of 5 stars0.00.00.04.70.03.31.3RVNCRevance Therapeutics2.6375 of 5 stars3.10.00.04.70.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.06Buy$172.3358.13% UpsideDRNADicerna Pharmaceuticals 0.00N/AN/AN/AMORFMorphic 2.00Hold$57.000.02% UpsideNGMNGM Biopharmaceuticals 0.00N/AN/AN/ARVNCRevance Therapeutics 2.13Hold$8.45131.51% UpsideCurrent Analyst Ratings BreakdownLatest DRNA, AXSM, RVNC, NGM, and MORF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$190.006/12/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/10/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.006/9/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$153.00 ➝ $150.006/3/2025AXSMAxsome TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$185.005/22/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/14/2025AXSMAxsome TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/7/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$200.00 ➝ $180.005/6/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$160.00 ➝ $165.005/6/2025AXSMAxsome TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$160.00 ➝ $162.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$432.16M12.42N/AN/A$1.18 per share92.36DRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77MORFMorphic$520K5,490.11N/AN/A$12.31 per share4.63NGMNGM Biopharmaceuticals$4.42M29.10N/AN/A$1.80 per share0.86RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.77N/A38.65N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)DRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AMORFMorphic-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/ANGMNGM Biopharmaceuticals-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/ARVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)Latest DRNA, AXSM, RVNC, NGM, and MORF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.04N/AN/AN/A$140.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AMORFMorphicN/AN/AN/AN/AN/ANGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics3.482.031.96DRNADicerna PharmaceuticalsN/A2.462.46MORFMorphicN/A24.1324.13NGMNGM BiopharmaceuticalsN/A7.797.79RVNCRevance TherapeuticsN/A4.123.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%DRNADicerna Pharmaceuticals78.91%MORFMorphic94.25%NGMNGM Biopharmaceuticals75.74%RVNCRevance Therapeutics97.70%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%DRNADicerna Pharmaceuticals10.20%MORFMorphic25.60%NGMNGM Biopharmaceuticals35.90%RVNCRevance Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.24 million38.26 millionOptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableMORFMorphic10050.09 million37.27 millionOptionableNGMNGM Biopharmaceuticals13883.46 million53.50 millionOptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableDRNA, AXSM, RVNC, NGM, and MORF HeadlinesRecent News About These CompaniesRevance Names New CEO to Drive Next Phase in Aesthetic InnovationMay 23, 2025 | globalcosmeticsnews.comGRevance Announces Leadership Succession Plan to Support Next Phase of Growth and InnovationMay 21, 2025 | finance.yahoo.comCrown Laboratories Now Operates Under the Name RevanceMarch 31, 2025 | finance.yahoo.comJohnson City-based Crown Labs now operating as ‘Revance’March 31, 2025 | wjhl.comWREVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMarch 6, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & KorsinskyMarch 4, 2025 | accessnewswire.comALevi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNCMarch 4, 2025 | accessnewswire.comARVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 4, 2025 | accessnewswire.comAContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | globenewswire.comContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | accessnewswire.comARevance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCMarch 4, 2025 | accessnewswire.comAFINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action LawsuitMarch 4, 2025 | accessnewswire.comAInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 4, 2025 | prnewswire.comInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 3, 2025 | accessnewswire.comAMarch 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCMarch 3, 2025 | accessnewswire.comARVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 3, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & KorsinskyMarch 3, 2025 | accessnewswire.comADeadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMarch 3, 2025 | businesswire.comRevance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNCMarch 3, 2025 | globenewswire.comLevi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming DeadlineMarch 3, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRNA, AXSM, RVNC, NGM, and MORF Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$108.98 -1.75 (-1.58%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$108.21 -0.77 (-0.71%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Dicerna Pharmaceuticals NASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Morphic NASDAQ:MORFMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.NGM Biopharmaceuticals NASDAQ:NGMNGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Revance Therapeutics NASDAQ:RVNCRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
